1. Introduction {#sec1}
===============

Obesity and related metabolic disorders are among the most important public-health concerns in developed nations \[[@B1]\]. One possible target for the reduction of obesity-related cardiometabolic risk is adiponectin, an adipokine with insulin-sensitizing and antiatherogenic properties, which circulates at levels inversely proportional to both total and abdominal fat mass \[[@B2]--[@B4]\]. Evidence suggests that an acute bout of vigorous aerobic exercise may result in a significant increase in plasma adiponectin levels in trained athletes, although this increase is not apparent until 30 minutes after the cessation of exercise \[[@B5]--[@B7]\]. In contrast, immediately following the cessation of exercise, adiponectin levels are reported to be unchanged \[[@B5]\] or even reduced \[[@B7]\] in trained individuals. Further, evidence also suggests that an acute bout of aerobic exercise at a moderate intensity has little or no impact on adiponectin levels in healthy, but untrained populations \[[@B8]\].

At present the relationship between an acute bout of aerobic exercise and adiponectin levels in inactive, abdominally obese individuals is unclear. Two studies have examined adiponectin levels immediately after exercise in this population \[[@B9], [@B10]\] and report that adiponectin levels are decreased \[[@B10]\] or unchanged \[[@B9]\]. However, to date no studies have examined adiponectin levels in abdominally obese individuals 30 minutes after the cessation of an acute bout of aerobic exercise, the time point when adiponectin has been reported to be increased in athletic populations \[[@B5], [@B7]\].

At present it is also unclear whether one week of aerobic exercise training is associated with an increase in plasma adiponectin levels in individuals with abdominal obesity. Kriketos et al. \[[@B11]\] report that 2 to 3 bouts of aerobic exercise spread over one week resulted in a dramatic 11.2 *μ*g/mL (equivalent to 160% of baseline values) increase in plasma adiponectin levels in inactive, abdominally obese men. An increase of this magnitude, however, is difficult to reconcile with other evidence. A recent systematic review reports that the average adiponectin increase observed in response to chronic exercise across all populations is just 1.33 *μ*g/mL, with the majority of studies, including those involving up to 24 weeks of regular exercise, failing to observe a significant change in adiponectin levels following the intervention \[[@B8]\]. Further, investigations of pharmacotherapy suggest similar small-to-moderate effects on adiponectin levels \[[@B12]\]. To our knowledge, the effect of a single week of aerobic training on adiponectin levels in a population of inactive and abdominally obese individuals has yet to be investigated, or corroborated, by any subsequent interventions.

Given the high prevalence of both hypoadiponectinemia and cardiometabolic risks among abdominally obese individuals \[[@B4]\], it is important to improve our understanding of the relationship between exercise and adiponectin levels in this high-risk population. The purpose of the present study was to examine the effect of both acute and short-term (\~1 week) aerobic exercise training on plasma adiponectin levels in inactive, abdominally obese men. We also sought to determine whether exercise intensity influences the response to plasma adiponectin levels in this population, independent of caloric expenditure. We hypothesized that adiponectin levels would be significantly decreased immediately following a bout of acute exercise, but significantly increased 30 minutes after the cessation of exercise, as well as after one week of aerobic training. We also hypothesized that for a given energy expenditure, exercising at 75% of VO~2~ peak would have a greater impact on adiponectin levels than exercising at 50% of VO~2~ peak.

2. Materials and Methods {#sec2}
========================

2.1. Participants {#sec2.1}
-----------------

Participants included 38 abdominally obese men (waist circumference ≥102 cm) aged 25 to 50 years. All participants reported being weight stable (±1 kg) for 6 months prior to the study and engaged in physical activity less than once per week. Potential participants were excluded from the study if they reported smoking or had a history of heart disease, stroke, or diabetes or were taking glucose-lowering medication. The use of lipid-lowering (e.g., statins) and hypertension (e.g., angiotensin-converting enzyme inhibitors) medications was permitted. All participants gave their informed written consent before participation in accordance with the ethical guidelines set by Queen\'s University. Participants were instructed to maintain their usual diet throughout the duration of the study.

2.2. Anthropometric Measurements {#sec2.2}
--------------------------------

Body mass was measured to the nearest 0.1 kg on a calibrated balance. Standing height was measured to the nearest 0.1 cm with the use of a wall-mounted stadiometer. Waist circumference (WC) was measured at the superior border of the iliac crest and was taken to the nearest 0.1 cm after a normal expiration.

2.3. Cardiorespiratory Fitness {#sec2.3}
------------------------------

Cardiorespiratory fitness (measured as oxygen consumption per unit of time (VO~2~ peak)) was determined using results of a maximal treadmill test combined with standard open-circuit spirometry techniques (SensorMedics Corp, Yorba Linda, California) at baseline. Fitness testing took place at least one week prior to the beginning of the exercise protocol for all participants.

2.4. Exercise Protocol {#sec2.4}
----------------------

Participants were randomly allocated to High- or Low-intensity treadmill exercise groups using a random number table. Group allocation was not revealed to individual participants until they arrived at their first exercise session. The High-intensity group exercised at a heart rate approximating an intensity of 75% of VO~2~ peak, while the Low-intensity group exercised at an intensity of 50% VO~2~ peak, as determined by the prestudy fitness test. The length of the exercise session was adjusted to ensure that each participant expended an estimated 400 calories per exercise session in order to investigate the impact of exercise intensity while keeping expenditure constant. Participants in both groups performed three bouts of aerobic exercise within one week, with one- to two-days of rest between each session.

2.5. Blood Samples and Biochemistry {#sec2.5}
-----------------------------------

All blood samples were taken following an overnight 12-hour fast. 10 mL of blood was taken from the antecubital vein immediately before, immediately after, and 30 minutes after the completion of the first exercise session. Blood samples were also taken 24--72 hours following the third and final exercise session. Plasma glucose was measured using an automated glucose analyzer (YSI 2300 Glucose Analyzer; YSI, Yellow Springs, OH). HDL-cholesterol and triglyceride levels were measured using enzymatic methods on the Roche Modular analytical system (Roche Diagnostics, Indianapolis, IN). Plasma adiponectin concentrations were determined using an enzyme-linked immunosorbent assay (B-Bridge International, Inc., San Jose, CA) of whole plasma kept at −80°C before use. All adiponectin measurements were performed centrally at the Cardiovascular Risk Factor Laboratory at the Quebec Heart and Lung Institute at Université Laval, Québec, Canada, and samples were shipped frozen using dry ice. Shifts in plasma volume during the acute bout of exercise were calculated using the method outlined by Dill and Costill \[[@B13]\].

2.6. Statistics {#sec2.6}
---------------

*T*-tests were used to compare baseline values between the two groups. A mixed-effect model with random intercept was used to assess changes in markers of cardiometabolic risk following a single session of aerobic exercise, as well as 24--72 hours after the third and final session of aerobic exercise. The following variables were included in the mixed-effect model for acute exercise: time of blood draw, group of participant, and changes in plasma volume. For short-term exercise, changes in plasma volume were omitted from the model. Statistical significance was defined as a *P* value of 0.05 or less, and a Bonferroni correction was used to adjust for multiple comparisons in post hoc tests following the mixed-effect model. All analyses of acute changes are controlled for changes in plasma volume.

Variables which exhibited nonnormal distributions were transformed prior to analysis using a log transformation. Five participants (3 from the High group, 2 from the Low group) participated in only the first exercise session and were thus excluded from analyses examining the impact of 3 exercise sessions on markers of metabolic risk. All analyses were performed using SAS 9.2 and SPSS 18.0.

3. Results {#sec3}
==========

Participant characteristics are presented in [Table 1](#tab1){ref-type="table"}. [Table 2](#tab2){ref-type="table"} displays values of adiponectin and other markers of cardiometabolic risk before and after a single session of aerobic exercise. Exercise at either a High- or Low-intensity resulted in a significant increase in adiponectin levels both immediately (High: *P* = 0.003; Low: *P* \< 0.0001) and 30 minutes after exercise (High: *P* = 0.0137; Low: *P* = 0.008). There was no significant group by time interaction (*P* = 0.8276). In comparison to baseline, triglyceride levels remained unchanged immediately following exercise in both groups (High: *P* = 0.2103; Low: *P* = 1.0) but were significantly decreased in the High-intensity group 30 minutes subsequent to exercise (*P* = 0.009). There was a borderline significant reduction of insulin levels immediately following the cessation of exercise in the Low-intensity group (*P* = 0.053), although they were no different from baseline 30 minutes following the cessation of exercise (*P* = 1.0). No changes in insulin levels were observed in the High-intensity group (*P* \> 0.05). Acute exercise did not result in any significant changes in any other marker of cardiometabolic risk (see [Table 2](#tab2){ref-type="table"}), and changes in adiponectin were not associated with changes in any other marker of cardiometabolic risk (data not shown, *P* \> 0.05).

[Table 3](#tab3){ref-type="table"} presents the levels of adiponectin and other markers of cardiometabolic risk before and after three sessions of aerobic exercise training at either a High or Low intensity. As expected, there were no significant changes in body weight or waist circumference in either group following one week of aerobic training (*P* \> 0.05). Adiponectin levels were significantly elevated in all participants 24--72 hours after the final exercise session (*P* \< 0.05), and these values were not significantly different from those observed following an acute bout of aerobic exercise (*P* \> 0.05) (see [Figure 1](#fig1){ref-type="fig"}). There was no significant group by time interaction (*P* = 0.6635). Three sessions of aerobic exercise did not result in significant changes in any other marker of cardiometabolic risk (*P* \> 0.05). Changes in adiponectin were not associated with changes in any marker of cardiometabolic risk except for fasting glucose (*r* = 0.40, *P* = 0.0234).

4. Discussion {#sec4}
=============

The present findings support our original hypotheses and suggest that an acute bout of aerobic exercise results in a significant increase in plasma adiponectin levels in abdominally obese men. Further, three sessions of aerobic exercise within a one-week period were sufficient to maintain this increase for 1--3 days after the final exercise session. It is worth noting that the increases in adiponectin observed in the present study occurred in the absence of any changes in weight or waist circumference. As such, these findings add to the growing body of evidence showing that exercise results in important health benefits irrespective of changes in body weight \[[@B14], [@B15]\].

The current findings are in agreement with previous work which has reported that vigorous exercise is associated with an acute increase in plasma adiponectin levels in trained athletes \[[@B5], [@B7]\]. These results also support the findings of Kriketos et al. \[[@B11]\], who report that one week of aerobic training results in increased adiponectin levels in abdominally obese men. It should be noted, however, that the increase in adiponectin levels following one week of training in the present study was of a much smaller magnitude than what has been reported previously \[[@B11]\].

In contrast to our hypothesis, the increase in adiponectin levels following a session of acute exercise was detectable immediately following the cessation of exercise. These results differ from the recent findings of Numao and colleagues \[[@B10]\], who report that adiponectin levels in abdominally obese men are significantly reduced immediately following the cessation of aerobic exercise at a high intensity and unchanged immediately following aerobic exercise at a low intensity. The reasons for these discrepant findings are not immediately clear. One difference worth noting, however, was that participants in the present study were almost exclusively Caucasian, while those involved in the study of Numao and colleagues were Japanese. Adiponectin has been shown to circulate in isoforms of varying molecular weights \[[@B16]\], and it has been reported that the relative proportions of these isoforms, and their relationships with disease, differ by ethnicity \[[@B17], [@B18]\]. For example, it has been reported that Indo-Asian women have a significantly lower proportion of high molecular weight adiponectin than their Caucasian peers \[[@B18]\]. Of note, Numao and colleagues report that although circulating levels of both medium- and low-molecular weight adiponectin decreased immediately following a bout of vigorous aerobic exercise, the proportion of high molecular weight adiponectin was significantly increased \[[@B10]\]. Thus, it is possible that ethnic differences in the relative proportions of adiponectin isoforms, or the response of these isoforms to acute exercise, may influence the relationship between exercise and total adiponectin levels. Unfortunately, the distribution of adiponectin isoforms was not assessed in the present study.

Differences between the current findings and those of Numao may also be related to the mode of exercise employed by the two studies. To our knowledge, only studies which have employed vigorous whole-body exercise report an acute increase in plasma adiponectin levels \[[@B5], [@B7]\]. In contrast, participants in the recent report by Numao et al. \[[@B10]\] performed exercise on a cycle ergometer, which may have engaged fewer muscle groups than the current intervention. Future research is needed to clarify the reasons behind these divergent findings.

4.1. Potential Mechanisms {#sec4.1}
-------------------------

Although it was once thought that adiponectin was produced exclusively in adipocytes, recent evidence suggests that adiponectin is also actively secreted by myocytes \[[@B19]--[@B21]\]. Further, Amin and colleagues have shown that the PPAR*γ* agonist rosiglitazone induces a significant increase in muscle adiponectin production \[[@B19]\]. Acute exercise has also been shown to result in rapid changes in the transcription of PPAR*γ* coactivator Pgc-1*α* in skeletal muscle, suggesting that this pathway may link acute exercise with adiponectin production at the level of the myocyte \[[@B22], [@B23]\]. However, to our knowledge no studies have yet examined the role of exercise in adiponectin production in muscle cells.

Although both insulin and catecholamine levels have been suggested to play a role in acute changes in adiponectin levels \[[@B7], [@B10], [@B24]\], they seem unlikely to explain the increases in adiponectin observed in the present study. In the present study, adiponectin levels were elevated above baseline in both groups at all postexercise time points, while insulin levels were only reduced at one time point (immediately following exercise) in one group (Low). This suggests that changes in insulin levels are not the primary mediator of the observed change in adiponectin levels. The role of catecholamines in this process is also unclear. While they are thought to play a largely inhibitory role in adiponectin expression \[[@B10], [@B25]\], it has also been shown that catecholamine levels are *increased* following vigorous exercise \[[@B26]\], which suggests that they too are unlikely to explain the present findings.

The present study has several strengths and limitations which warrant mention. As mentioned previously, the present analysis focused solely on total adiponectin concentrations, rather than looking at concentrations of specific adiponectin oligomers. The current study also focused exclusively on a relatively homogeneous group of inactive, abdominally obese adult males, and thus our findings may not translate to females or to individuals with ages or phenotypes different from those of participants in the current sample. While this may limit the generalizability of these results to other groups, the population studied in the current investigation is at substantially increased risk of hypoadiponectinemia and cardiometabolic dysfunction \[[@B4]\]. As a result, interventions which are able to increase adiponectin levels in this population could have important clinical applications. Finally, the current investigation also benefits from a randomized design and the tight monitoring and control of exercise intensity for participants in both groups.

In summary these findings suggest that an acute bout of exercise, regardless of exercise intensity, results in a significant increase in plasma adiponectin levels in inactive, abdominally obese men. Further, an acute bout of exercise at high, but not low, intensity also results in a significant reduction in plasma triglyceride levels in these same individuals. Finally, adiponectin levels remained elevated 24--72 hours after completing 3 exercise sessions in a one-week period. These changes were observed in the absence of any change in weight or body composition. These results suggest that positive changes in adiponectin levels may be yet another important health benefit observed with even a single session of aerobic exercise.
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###### 

Participant characteristics.

                                    Low (*n* = 18)   High (*n* = 20)
  --------------------------------- ---------------- -----------------
  Age                               38.39 (11.2)     38.95 (7.6)
  BMI (kg/m^2^)                     33.00 (3.8)      33.96 (3.6)
  Waist circumference (cm)          112.97 (8.7)     117.10 (8.9)
  Systolic blood pressure (mmHg)    124.33 (15.7)    116.65 (30.1)
  Diastolic blood pressure (mmHg)   82.94 (7.8)      77.2 (19.8)
  VO~2~ peak (mL/kg/min)            32.00 (4.59)     32.83 (6.1)
  Exercise volume (min)             48.6 (6.6)       30.75 (6.1)\*
  Average intensity (% of max)      47.9% (3.9)      72.6% (4.3)\*
  Calories burned (kcal)            383.32 (36.2)    394.4 (29.7)

Data are presented as mean (Standard Deviation).

\*Significantly different from the Low group, *P* ≤ 0.05.

###### 

Acute changes in markers of cardiometabolic risk following one bout of aerobic exercise.

                             Group            Before exercise   Following exercise   Following exercise + 30
  -------------------------- ---------------- ----------------- -------------------- -------------------------
  Adiponectin (ug/mL)        High             5.05 (0.41)       5.79 (0.42)\*        5.69 (0.42)\*
  Low                        4.37 (0.44)      5.24 (0.44)\*     5.11 (0.44)\*        
  Triglycerides (mmol/L)     High             1.98 (0.24)       2.10 (0.24)          1.77 (0.24)\*
  Low                        2.04 (0.26)      2.09 (0.26)       1.93 (0.26)          
  HDL cholesterol (mmol/L)   High             1.04 (0.053)      1.06 (0.054)         0.99 (0.053)
  Low                        0.81 (0.056)     0.88 (0.056)      0.84 (0.059)         
  LDL cholesterol (mmol/L    High             3.62 (0.23)       3.60 (0.23)          3.53 (0.23)
  Low                        2.89 (0.25)      2.90 (0.25)       2.86 (0.25)          
  Insulin (pmol/L)           High             85.05 (7.74)      85.63 (7.47)         91.63 (9.11)
  Low                        108.38 (24.67)   68.25 (11.27)     79.44 (14.85)        
  Glucose (mmol/L)           High             5.44 (0.15)       5.60 (0.16)          5.45 (0.15)
  Low                        4.83 (0.17)      4.75 (0.17)^†^    4.73 (0.17)^†^       

Data presented as mean (standard error). All acute data are controlled for changes in plasma volume.

\*Significantly different from baseline, *P* ≤ 0.05, using Bonferroni correction.

^†^Significantly different from High-intensity group at the same time point *P* ≤ 0.05, using Bonferroni correction.

###### 

Changes in markers of cardiometabolic risk following one week of aerobic exercise training.

                             Group             Before training   After training
  -------------------------- ----------------- ----------------- ----------------
  Adiponectin (ug/mL)        High              4.86 (0.48)       5.47 (0.48)\*
  Low                        4.47 (0.49)       5.18 (0.49)\*     
  Triglycerides (mmol/L)     High              2.07 (0.27)       1.71 (0.27)
  Low                        2.06 (0.28)       2.27 (0.27)       
  HDL Cholesterol (mmol/L)   High              1.04 (0.059)      1.00 (0.06)
  Low                        0.77 (0.061)^†^   0.95 (0.06        
  LDL Cholesterol (mmol/L    High              3.58 (0.25)       3.48 (0.25)
  Low                        2.91 (0.25)       3.07 (0.25)       
  Insulin (pmol/L)           High              85.05 (7.74)      73.00 (10.52)
  Low                        108.38 (24.67)    90.13 (15.15)     
  Glucose (mmol/L)           High              5.36 (0.15)       5.55 (0.15)
  Low                        4.92 (0.17)       5.05 (0.16)       
  Weight (kg)                High              114.48 (4.03)     114.49 (4.03)
  Low                        105.42 (4.16)     104.72 (4.16)     
  Waist Circumference (cm)   High              118.50 (2.07)     117.55 (2.07)
  Low                        112.92 (2.13)     112.71 (2.14)     

Data presented as mean (standard error).

\*Significantly different from baseline, *P* ≤ 0.05, using Bonferroni correction.

^†^Significantly different from High-intensity group at the same time point *P* ≤ 0.05, using Bonferroni correction.
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